A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
Condition(s) studied
Investigational drug(s) / intervention(s)
Ocrelizumab: Ocrelizumab is administered as two infusions of half the dose given 14 days apart for the first dose, then subsequent doses are administered as a single infusion every 24 weeks. Cohort 1: total dose of 300 mg Cohort 2: total dose of 600 mg Cohort 3 and 4: additional dose level(s) may be lower than 300 mg, between 300 mg and 600 mg, or higher than 600 mg, but will be no higher than 1200 mg
Study summary
This 12-year study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages ≥ 10 to ≤ 18 years with relapsing-remitting multiple sclerosis (RRMS). The data from this study will serve to determine the dosing regimen of ocrelizumab to be further investigated in the subsequent Phase III study in children and adolescents.
Eligibility
Primary outcome measure(s)
- Dose Exploration Period: Area Under the Concentration Versus Time Curve of Ocrelizumab — Pre-dose 5- 30 minutes and post-dose 30 mins on Days 1, 15 and 169; At any time on Days 29, 57, 85 and 113
The population PK model was used to simulate concentration-time course and predict individual area under the concentration versus time curve. The data for the PK parameter: area under the concentration versus time curve was collected and analyzed as per body weight range (\<40kg to ≥40 kg). - Dose Exploration Period: Maximum Concentration (Cmax) of Ocrelizumab — Pre-dose 5- 30 minutes and post-dose 30 mins on Days 1, 15 and 169; At any time on Days 29, 57, 85 and 113
The population PK model was used to simulate concentration-time course and predict individual Cmax. The data for the PK parameter: Cmax was collected and analyzed as per body weight range (\<40kg to ≥40 kg). - Dose Exploration Period: Levels of CD 19+ B-cell Count in Blood — At Week 24
Trial sites (12)
| Facility | City | Region | Status |
|---|---|---|---|
| University of Colorado Denver Childrens Hospital Rocky Mountain MS Center | Aurora | Colorado | |
| Childrens National Health Center | Washington D.C. | District of Columbia | |
| Boston Childrens Hospital | Boston | Massachusetts | |
| Washington Universtiy school of Medicine | St Louis | Missouri | |
| Cleveland Clinic | Cleveland | Ohio | |
| Ospedale Pediatrico Bambino Gesù | Rome | Lazio | |
| Azienda Ospedaliera Sant'Andrea | Rome | Lazio | |
| AOU Policlinico V. Emanuele - P.O G. Rodolico | Catania | Sicily | |
| Uniwersyteckie Centrum Kliniczne | Gda?sk | Poland | |
| Uniwersytecki Szpital Kliniczny w Poznaniu | Późna | Poland | |
| Dzieci?cy Szpital Kliniczny im. Józefa Polikarpa Brudzi?skiego | Warsaw | Poland | |
| Instytut Pomnik Centrum Zdrowia Dziecka | Warsaw | Poland |
On this site
📄 Ocrevus (ocrelizumab) drug profile →More Hoffmann-La Roche trials in Italy
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04075266 on ClinicalTrials.gov ↗ ← All trials in Italy